Unknown

Dataset Information

0

Immunotherapy in progressive supranuclear palsy.


ABSTRACT:

Purpose of review

Progressive supranuclear palsy (PSP) is a progressive adult-onset neurodegenerative disease. Abnormally, phosphorylated forms of the microtubule-associated protein tau containing four repeat domains (4R-tau) aggregate in neurons. Additionally, increasing evidence suggests that secretion and uptake of fragments of abnormal 4R-tau may play a role in disease progression. This extracellular tau is a natural target for immunotherapy.

Recent findings

Three monoclonal antibodies targeting extracellular tau are in clinical stages of development. ABBV-8E12 and BIIB092 were safe in Phase 1, but both Phase two studies recently failed futility analyses. UCB0107 recently reported (in abstract form) Phase 1 safety results, and a Phase 2 study is under consideration. Stem cell therapy and the infusion of plasma are also being explored clinically.

Summary

The likely role of extracellular tau in the progression of PSP makes tau a natural target for targeted immunotherapy. Clinical trials are still in early stages, and although tau immunotherapy has largely been shown to be safe, efficacy has yet to be demonstrated.

SUBMITTER: Vaswani PA 

PROVIDER: S-EPMC7722007 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4887294 | biostudies-literature
| S-EPMC4572662 | biostudies-literature
| S-EPMC7011663 | biostudies-literature
2021-12-05 | GSE186921 | GEO
| S-EPMC4734991 | biostudies-literature
| S-EPMC3589239 | biostudies-literature
| S-EPMC8281359 | biostudies-literature
| S-EPMC7375943 | biostudies-literature
| S-EPMC8376988 | biostudies-literature
| S-EPMC8095545 | biostudies-literature